Composition for inducing proliferation or accumulation of regulatory T cells
It was found that bacteria belonging to the genus Clostridium induce accumulation of regulatory T cells (Treg cells) in the colon. Moreover, the present inventors found that regulatory T cells (Treg cells) induced by from these bacteria suppressed proliferation of effector T-cells. From these findings, the present inventors found that the use of bacteria belonging to the genus Clostridium or a physiologically active substance derived therefrom made it possible to induce proliferation or accumulation of regulatory T cells (Treg cells), and further to suppress immune functions.
1. A pharmaceutical composition comprising a spore-forming fraction of human fecal matter formulated for delivery to the intestine, wherein the composition induces proliferation and/or accumulation of regulatory T cells, wherein the spore-forming fraction is resistant to chloroform, and wherein the composition is formulated for oral administration.
2. The pharmaceutical composition of claim 1 , wherein the spore-forming fraction is obtained by chloroform treatment of human fecal matter.
3. The pharmaceutical composition of claim 2 , wherein the chloroform treatment includes an incubation step with chloroform of about 1 hour.
4. The pharmaceutical composition of claim 3 , wherein the chloroform treatment includes a step of removal of chloroform with nitrogen gas.
5. The pharmaceutical composition of claim 1 , wherein the composition further comprises a pharmacologically acceptable carrier.
6. The pharmaceutical composition of claim 1 , wherein the composition is in the form of a capsule.
7. The pharmaceutical composition of claim 1 , wherein the composition is formulated for delivery to the colon.
8. The pharmaceutical composition of claim 1 , wherein the composition further comprises a pH sensitive composition comprising one or more enteric polymers.
9. A pharmaceutical composition comprising a spore-forming fraction of human fecal matter formulated for delivery to the intestine, wherein the composition induces proliferation and/or accumulation of regulatory T cells, wherein the spore-forming fraction is resistant to heat, and wherein the composition is formulated for oral administration.
10. The pharmaceutical composition of claim 9 , wherein the spore-forming fraction is obtained by chloroform treatment of human fecal matter.
11. The pharmaceutical composition of claim 10 , wherein the chloroform treatment includes an incubation step with chloroform of about 1 hour.
12. The pharmaceutical composition of claim 11 , wherein the chloroform treatment includes a step of removal of chloroform with nitrogen gas.
13. The pharmaceutical composition of claim 9 , wherein the composition further comprises a pharmacologically acceptable carrier.
14. The pharmaceutical composition of claim 9 , wherein the composition is in the form of a capsule.
15. The pharmaceutical composition of claim 9 , wherein the composition is formulated for delivery to the colon.
16. The pharmaceutical composition of claim 9 , wherein the composition further comprises a pH sensitive composition comprising one or more enteric polymers.
17. A pharmaceutical composition comprising an active ingredient, wherein the active ingredient consists of a spore-forming fraction of human fecal matter, wherein the composition is formulated for delivery to the intestine, wherein the composition induces proliferation and/or accumulation of regulatory T cells, and wherein the composition is formulated for oral administration.
18. The pharmaceutical composition of claim 17 , wherein the spore-forming fraction is resistant to chloroform.
19. The pharmaceutical composition of claim 18 , wherein the spore-forming fraction is obtained by chloroform treatment of human fecal matter.
20. The pharmaceutical composition of claim 19 , wherein the chloroform treatment includes an incubation step with chloroform of about 1 hour.
21. The pharmaceutical composition of claim 20 , wherein the chloroform treatment includes a step of removal of chloroform with nitrogen gas.
22. The pharmaceutical composition of claim 17 , wherein the spore-forming fraction is resistant to heat.
23. The pharmaceutical composition of claim 17 , wherein the composition further comprises a pharmacologically acceptable carrier.
24. The pharmaceutical composition of claim 17 , wherein the composition is in the form of a capsule.
25. The pharmaceutical composition of claim 17 , wherein the composition is formulated for delivery to the colon.
26. The pharmaceutical composition of claim 17 , wherein the composition further comprises a pH sensitive composition comprising one or more enteric polymers.
27. The pharmaceutical composition of claim 1 , wherein the composition does not include Bacteroides.
28. The pharmaceutical composition of claim 9 , wherein the composition does not include Bacteroides.